COR is staging its sharpest recovery in months, up 5.6% on the week to $279.57, yet the stock is still nursing a steep year-to-date hole — and the most interesting tension right now is the gap between a genuinely bullish options picture and a Street that keeps cutting price targets even while holding positive ratings.
The options market has swung hard toward the bullish end. The put/call ratio has collapsed to 0.39, well below its 20-day average of 0.41 and near the 52-week low of 0.31. Just three weeks ago — during the post-earnings rout in early May — the PCR was running above 0.62, reflecting heavy demand for downside protection. That defensive overhang has almost entirely unwound in the space of a month. Call activity is now dominant, suggesting options traders have largely moved on from the May 6 earnings shock that sent the stock down 16% in a single session.
The lending market offers no real drama to counter that bullish tone. Short interest at 2.9% of free float is modest, up about 10% on the week but still near the low end of the stock's historical range. Borrowing costs are effectively zero at 0.5%, and borrow availability is extraordinarily loose — roughly 6,200% relative to shares already borrowed, meaning there is no meaningful constraint on either side of the trade. The short score of 34.6 is nudging higher from 33.5 a week ago, but it remains firmly in the lower half of the range and reflects a setup that is cautious rather than bearish.
The Street is telling a more complicated story. Analysts remain broadly bullish in direction — the consensus is still constructive, with a mean price target of $350.58 implying roughly 25% upside from current levels. But the direction of recent target revisions is telling. Barclays cut its target this week to $350 from $425 while maintaining Overweight, following similar moves from Wells Fargo, Citigroup, and Baird in the days after the May earnings print. The shared pattern: hold the positive rating, slash the target. The EV/EBITDA multiple has edged up to 10.8x over the past 30 days as the stock recovers, and the PE has climbed to around 15x — neither stretched, but the multiple expansion is happening before the earnings revision cycle has fully reset. The EPS surprise factor score ranks in the 89th percentile, suggesting the company has historically delivered above consensus — which makes the May miss all the more jarring to the Street's models.
The institutional holder list is stable and long-oriented. BlackRock holds just over 10% of shares and added around 362,000 shares in the most recent reported period. T. Rowe Price holds nearly 7%, with a substantial build-up recorded through March. One holder worth noting is Walgreens Boots Alliance Holdings, which carries a 4.9% stake and reported no change — a static anchor position from a related-industry player. Chairman Dermot Durcan purchased $1.1 million of stock in the open market on May 28 at $266.26, a modest but clean signal of insider conviction near the post-earnings lows. The CEO sold shares in January and February at prices well above $350, which provides context but reflects pre-crash levels.
The peer group is moving broadly in the same direction. CAH gained 9.1% on the week and MCK added 6.4%, so COR's 5.6% recovery is actually trailing the two closest distributor peers. That mild underperformance within the group is worth watching into the next earnings print, scheduled for August 5 — whether COR's options sentiment and analyst target gap begin to converge with peers, or whether the May shock continues to cast a longer shadow than it has for Cardinal and McKesson, is the question the data will answer over the next six weeks.
See the live data behind this article on ORTEX.
Open COR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
